Wednesday, July 8, 2026

pharma · Hypercholesterolemia · Hyperlipidemia · ESPR

Esperion Therapeutics

Espervita Therapeutics is a pharma organization headquartered in ann arbor, USA. It trades on NYSE under ticker ESPR. Primary therapeutic focus areas include Hypercholesterolemia, Hyperlipidemia, Cardiovascular Diseases,

Ann Arbor, US HQ
5 Employees
Public company Type
ESPR · NYSE Ticker
Company details
Status
Public
HQ
Ann Arbor, US
Employees
5
Programs
15
Drugs
9
Patents
55
Clinical program

ETC-1002

Phase 1 · small molecule · Safety Evaluation of Escalating Doses

ETC-1002 for Safety Evaluation of Escalating Doses is a Phase 1 program (small_molecule) at Esperion Therapeutics with 1 ClinicalTrials.gov record(s).

← All Esperion Therapeutics projects Phase 1 small molecule completed

Internal code ETC-1002-004

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Esperion Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Safety Evaluation of Escalating Doses
Status
completed
Trials
1

Clinical trials